NCT02502266 2026-03-05
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
Clinical Trials
22 trialsNCT01012817 2025-09-15
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT02569957 2025-05-04
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT02487095 2025-04-13
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT00170625 2024-11-12
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 1/2 Completed
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT00317772 2022-02-07
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed
NCT02421588 2020-04-03
CORAIL
PharmaMar
Phase 3 Completed
NCT00011986 2019-04-16
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Phase 3 Completed
NCT00114166 2018-07-24
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00720096 2018-01-02
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT02100007 2017-10-02
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
Phase 1/2 Terminated
NCT01684878 2017-05-23
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
Hoffmann-La Roche
Phase 3 Completed
NCT01003938 2016-06-30
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
NYU Langone Health
Phase 2 Terminated
NCT00526799 2016-03-03
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00343044 2015-05-15
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Benaroya Research Institute
Phase 2 Completed
NCT00436644 2014-04-16
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
Mayo Clinic
Phase 2 Completed
NCT00316173 2012-11-27
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
GlaxoSmithKline
Phase 2 Completed